Thetis Receives Funds From Crohn’s & Colitis Foundation to Further Develop TP-317 for IBD
News
The Crohn’s & Colitis Foundation is providing funding support to Thetis Pharmaceuticals for the continuing development of the novel oral therapy TP-317 for the treatment of inflammatory bowel disease (IBD). ... Read more